Natco Pharma to Launch Semaglutide at Rs 1,290 in India

Introduction

Hyderabad-based Natco Pharma is set to launch its generic semaglutide injection in India, a move that will significantly alter the landscape for diabetes and weight management treatments. The launch, scheduled for March 21, 2026, follows the patent expiry of the innovator drug and introduces a highly affordable alternative to the market, with prices starting as low as Rs 1,290 per month.

Regulatory Approval and Launch Timeline

Natco Pharma received approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market the drug. This approval was granted after the company successfully completed a clinical comparison study, ensuring its generic version is on par with the original. The company plans a phased rollout, beginning with multi-dose vials immediately after the patent for Novo Nordisk's Ozempic expires on March 20, 2026. A pen-device version is expected to follow in April 2026.

A New Pricing Benchmark

The company's pricing strategy is its most disruptive feature. The generic semaglutide will be marketed under the brand names SEMANAT and SEMAFULL. The initial launch will feature multi-dose vials, which are priced to maximize accessibility. This vial-based therapy is positioned as approximately 70% cheaper than existing pen devices and nearly 90% less expensive than the innovator's brand, making it the most affordable GLP-1 therapy in India.

Product and Pricing Details

Natco has outlined a clear pricing structure for its different product formats. The multi-dose vials are designed for affordability, while the upcoming pen devices will offer convenience at a competitive price point. This dual-format strategy aims to cater to a wider range of patient needs and preferences.

Market Context and Competitive Landscape

The patent expiry for semaglutide has opened the door for several generic manufacturers to enter the Indian market. Besides Natco Pharma, major players like Sun Pharma, Dr. Reddy's Laboratories, and Zydus Lifesciences are also expected to launch their versions. This influx of competition is anticipated to drive down prices further, with analysts predicting the market could grow tenfold in the coming years as access to the therapy expands dramatically.

Strategic Partnerships and Commercialization

To ensure broad market reach, Natco Pharma is pursuing a multi-pronged commercial strategy. The company is the first in India to offer generic semaglutide in multi-dose vials with customized syringes. In addition to its own marketing efforts, Natco is offering the product to third parties for co-marketing. A key development is the strategic partnership with Ahmedabad-based Eris Lifesciences, which will commercialize the semaglutide formulation in India, leveraging its strong presence in the diabetes and metabolic care segment.

Investor Reaction and Stock Performance

The announcement of the affordable semaglutide launch was met with a positive response from the market. On March 20, 2026, shares of Natco Pharma saw a significant uptick. The stock was trading at Rs 966.80, a gain of Rs 28.75 or 3.06% from its previous close. The share price touched an intraday high of Rs 972.50, reflecting investor confidence in the company's strategic move and its potential to capture a substantial share of the growing GLP-1 market.

Impact on Patients and Healthcare

The primary indication for semaglutide is for adults with insufficiently controlled type 2 diabetes, used as an adjunct to diet and exercise. It is also widely used for obesity management. The high cost of the innovator drug has been a significant barrier to access for many patients in India. Natco's low-cost generic is expected to improve patient access and support long-term treatment adherence, addressing a critical need in the management of chronic metabolic disorders.

Conclusion

Natco Pharma's launch of generic semaglutide at a disruptive price point marks a pivotal moment for diabetes and obesity treatment in India. By making this advanced therapy significantly more affordable, the company is poised to not only gain a strong market position but also contribute to better health outcomes for a large patient population. The upcoming launch of its pen device in April and the intensifying competition will be key developments to watch in this rapidly evolving market segment.